

For Immediate Release:

December 11, 2008

Contact:

Mary Kuramoto

513-579-9911 X 2523

m.kuramoto@medpace.com

Medpace adds Medical Director, Dr. Bernard E. Ilson, MD, FACP building their Clinical Expertise in Nephrology and Clinical Pharmacology

CINCINNATI (December 10, 2008) — Medpace, Inc. today announced the addition of Dr. Bernard E. Ilson MD, FACP, as Medical Director building on their therapeutic focus in nephrology and broadening strength in clinical pharmacology.

Dr. Ilson has over 21 years of experience in clinical drug development with GlaxoSmithKline Pharmaceuticals and Cardiokine. Dr. Ilson brings an extensive drug development experience to Medpace, spanning Phases I-IV. During his tenure with GSK, Dr. Ilson carried several drugs through from early phase development to regulatory approval and product launch, including Teveten and Coreg. Dr. Ilson had been head of the Cardiovascular and Metabolic Therapy areas within Clinical Pharmacology, Full Development with responsibility for late phase development of several novel drug products, in licensing and product line extensions. He was responsible for the design and conduct of Levitra and Vesicare thorough QT studies, resulting in regulatory approval of both drugs, and he took a leading role in establishing GSK's strategy in the clinical evaluation of arrhythmia risk of new chemical entities. More recently, Dr. Ilson served as Chief Medical Officer of Cardiokine, a specialty pharmaceutical company focused on the development of pharmaceuticals for the treatment and prevention of heart failure and related cardiovascular indications.

“We are pleased that Dr. Ilson has joined Medpace as a Medical Director,” said Dr. August Troendle, Medpace President and CEO. “Dr. Ilson’s reputation as an academic leader in nephrology, combined with his years of experience in clinical development makes him a perfect fit to support Medpace’s continued growth as a global provider of therapeutic expertise as well as a strong partner with our pharmaceutical sponsors.”

Dr. Ilson received his undergraduate (B.S., Biology) and graduate degrees (M.S., Biochemistry) at the University of Connecticut before matriculating at the NYU School of Medicine. Subsequent to receiving his medical degree from NYU, Dr. Ilson completed Internal Medicine training at the Medical College of Virginia in Richmond and then completed a Nephrology/Hypertension fellowship at Temple University Hospital. In addition to his duties at GSK, Dr. Ilson was Clinical Associate Professor of Medicine at the Presbyterian Medical Center of Philadelphia, affiliate of University of Pennsylvania School of Medicine where he had an academic practice of nephrology for 12 years. Dr. Ilson is board certified in Internal Medicine, Nephrology/Hypertension and Clinical Pharmacology.

###

ABOUT MEDPACE

Medpace is a leading global full-service clinical research organization led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, and oncology. Medpace has assembled the industry's most experienced and therapeutically focused team to execute at every level of the company's operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.

With more than 700 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide within the core therapeutic areas of cardiology, metabolism, and oncology.

Medpace provides centralized image management and reading from Imagepace, centralized laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and Phase I / IIa research services from Medpace Clinical Pharmacology.

Visit the Medpace website at www.medpace.com